Heart failure drug treatment

[1]  E. Nilsson,et al.  A real-world cohort study on the quality of potassium and creatinine monitoring during initiation of mineralocorticoid receptor antagonists in patients with heart failure , 2018, European heart journal. Quality of care & clinical outcomes.

[2]  F. Zannad,et al.  Cardiorenal Syndrome Revisited , 2018, Circulation.

[3]  R. Carter,et al.  A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction , 2018, Circulation.

[4]  J. Cleland,et al.  Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease , 2018, The New England journal of medicine.

[5]  G. Filippatos,et al.  Comprehensive in‐hospital monitoring in acute heart failure: applications for clinical practice and future directions for research. A statement from the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) , 2018, European journal of heart failure.

[6]  F. Alla,et al.  Impact of the interruption of a large heart failure regional disease management programme on hospital admission rates: a population‐based study , 2018, European Journal of Heart Failure.

[7]  M. Gheorghiade,et al.  Lessons learned in acute heart failure , 2018, European journal of heart failure.

[8]  Rui Placido,et al.  Acutely decompensated heart failure with preserved and reduced ejection fraction present with comparable haemodynamic congestion , 2018, European journal of heart failure.

[9]  S. Solomon,et al.  Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus , 2018, Circulation.

[10]  P. Ponikowski,et al.  Acute heart failure: lessons learned, roads ahead , 2018, European journal of heart failure.

[11]  J. McMurray,et al.  Multimorbidity in patients with heart failure from 11 Asian regions: A prospective cohort study using the ASIAN-HF registry , 2018, PLoS medicine.

[12]  S. Solomon,et al.  Contribution of cardiac and extra‐cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure , 2018, European journal of heart failure.

[13]  J. Januzzi,et al.  The Future of Biomarker-Guided Therapy for Heart Failure After the Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) Study , 2018, Current Heart Failure Reports.

[14]  B. Zinman,et al.  Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial , 2018, European heart journal.

[15]  A. Cohen-Solal,et al.  Heart failure oral therapies at discharge are associated with better outcome in acute heart failure: a propensity‐score matched study , 2018, European journal of heart failure.

[16]  A. Folsom,et al.  Six-Year Changes in Physical Activity and the Risk of Incident Heart Failure: The Atherosclerosis Risk in Communities (ARIC) Study , 2018 .

[17]  A. Mebazaa,et al.  Integrative Assessment of Congestion in Heart Failure Throughout the Patient Journey. , 2017, JACC. Heart failure.

[18]  Faiez Zannad,et al.  Rising incidence of heart failure demands action , 2017, The Lancet.

[19]  S. Heymans,et al.  Rationale of the FIBROTARGETS study designed to identify novel biomarkers of myocardial fibrosis , 2017, ESC heart failure.

[20]  M. Packer.  Acute Heart Failure Is an Event Rather Than a Disease: Plea for a Radical Change in Thinking and in Therapeutic Drug Development. , 2018, JACC. Heart failure.

[21]  Hyun-Young Park,et al.  Comparative Effectiveness of Telemonitoring Versus Usual Care for Heart Failure: A Systematic Review and Meta-analysis. , 2018, Journal of cardiac failure.

[22]  A. Mebazaa.  Acute Heart Failure Deserves a Log-Scale Boost in Research Support: Call for Multidisciplinary and Universal Actions. , 2018, JACC. Heart failure.

[23]  Roland A Matsouaka,et al.  Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes. , 2017, Journal of the American College of Cardiology.

[24]  G. Filippatos,et al.  Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long‐Term Registry , 2017, European journal of heart failure.

[25]  Sanjiv J. Shah,et al.  The potential role and rationale for treatment of heart failure with sodium–glucose co‐transporter 2 inhibitors , 2017, European journal of heart failure.

[26]  K. Anstrom,et al.  Effect of Natriuretic Peptide–Guided Therapy on Hospitalization or Cardiovascular Mortality in High-Risk Patients With Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial , 2017, JAMA.

[27]  Gerasimos S Filippatos,et al.  2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. , 2017, Journal of the American College of Cardiology.

[28]  S. Solomon,et al.  Declining Risk of Sudden Death in Heart Failure , 2017, The New England journal of medicine.

[29]  Andreas Schäfer,et al.  Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) , 2017, European journal of heart failure.

[30]  Akshay S. Desai,et al.  Angiotensin Receptor Neprilysin Inhibition in Heart Failure With Preserved Ejection Fraction: Rationale and Design of the PARAGON-HF Trial. , 2017, JACC. Heart failure.

[31]  P. Ponikowski,et al.  Determinants and clinical outcome of uptitration of ACE-inhibitors and beta-blockers in patients with heart failure: a prospective European study , 2017, European heart journal.

[32]  G. Fonarow,et al.  Extracorporeal Ultrafiltration for Fluid Overload in Heart Failure , 2017, Journal of the American College of Cardiology.

[33]  P. Ponikowski,et al.  Physicians' guideline adherence is associated with better prognosis in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry , 2017, European journal of heart failure.

[34]  Mark D. Huffman,et al.  Global mortality variations in patients with heart failure: results from the International Congestive Heart Failure (INTER-CHF) prospective cohort study. , 2017, The Lancet. Global health.

[35]  M. Mcclellan,et al.  Moving Beyond the Walls of the Clinic: Opportunities and Challenges to the Future of Telehealth in Heart Failure. , 2017, JACC. Heart failure.

[36]  Sanjiv J. Shah,et al.  Vericiguat in patients with worsening chronic heart failure and preserved ejection fraction: results of the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED EF (SOCRATES-PRESERVED) study , 2017, European heart journal.

[37]  G. Filippatos,et al.  European Society of Cardiology Heart Failure Long‐Term Registry (ESC‐HF‐LT): 1‐year follow‐up outcomes and differences across regions , 2016, European journal of heart failure.

[38]  Yi Zhang,et al.  A Multisensor Algorithm Predicts Heart Failure Events in Patients With Implanted Devices: Results From the MultiSENSE Study. , 2017, JACC. Heart failure.

[39]  A. Cohen-Solal,et al.  Precipitating factors and 90‐day outcome of acute heart failure: a report from the intercontinental GREAT registry , 2017, European journal of heart failure.

[40]  J. McMurray,et al.  Thirty Years of Evidence on the Efficacy of Drug Treatments for Chronic Heart Failure With Reduced Ejection Fraction , 2017, Circulation. Heart failure.

[41]  Maurizio Taramasso,et al.  Diagnosis and treatment of tricuspid valve disease: current and future perspectives , 2016, The Lancet.

[42]  M. Redfield.  Heart Failure with Preserved Ejection Fraction. , 2016, The New England journal of medicine.

[43]  P. Ponikowski,et al.  [2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure]. , 2016, Kardiologia polska.

[44]  I. Piña,et al.  Hyperkalemia in Heart Failure. , 2016, Journal of the American College of Cardiology.

[45]  A. Mebazaa,et al.  Effectiveness of a multidisciplinary heart failure disease management programme on 1-year mortality , 2016, Medicine.

[46]  I. Eržen,et al.  National trends in heart failure hospitalization rates in Slovenia 2004–2012 , 2016, European journal of heart failure.

[47]  P. Kirchhof,et al.  2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, European heart journal.

[48]  F. Zannad,et al.  Antithrombotic therapy in heart failure patients with and without atrial fibrillation: update and future challenges. , 2016, European heart journal.

[49]  R. Wachter,et al.  Heart failure epidemiology 2000–2013: insights from the German Federal Health Monitoring System , 2016, European journal of heart failure.

[50]  Volkmar Falk,et al.  2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2016, Revista espanola de cardiologia.

[51]  Sanjiv J. Shah,et al.  The HFpEF Obesity Phenotype: The Elephant in the Room. , 2016, Journal of the American College of Cardiology.

[52]  J. Mascherbauer,et al.  Functional Status, Pulmonary Artery Pressure, and Clinical Outcomes in Heart Failure With Preserved Ejection Fraction. , 2016, Journal of the American College of Cardiology.

[53]  Adrian F Hernandez,et al.  Trends in 30-Day Readmission Rates for Patients Hospitalized With Heart Failure: Findings From the Get With The Guidelines-Heart Failure Registry. , 2016, Circulation. Heart failure.

[54]  Martin B Leon,et al.  Management strategies and future challenges for aortic valve disease , 2016, The Lancet.

[55]  M. Mack,et al.  Mitral valve disease—current management and future challenges , 2016, The Lancet.

[56]  G. Parati,et al.  Effects of blood pressure-lowering treatment. 6. Prevention of heart failure and new-onset heart failure – meta-analyses of randomized trials , 2016, Journal of hypertension.

[57]  E. Colín-Ramírez,et al.  Salt in the diet in patients with heart failure: what to recommend , 2016, Current opinion in cardiology.

[58]  W. Kraus,et al.  Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial. , 2016, JAMA.

[59]  G. Fonarow,et al.  The Prevention of Hospital Readmissions in Heart Failure. , 2016, Progress in cardiovascular diseases.

[60]  Gabriel A. Koepp,et al.  Isosorbide Mononitrate in Heart Failure with Preserved Ejection Fraction. , 2015, The New England journal of medicine.

[61]  B. Zinman,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.

[62]  E. Peterson,et al.  Consistency of Laboratory Monitoring During Initiation of Mineralocorticoid Receptor Antagonist Therapy in Patients With Heart Failure. , 2015, JAMA.

[63]  R. D. de Boer,et al.  Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial. , 2015, European heart journal.

[64]  N. Oestreicher,et al.  Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. , 2015, The American journal of managed care.

[65]  Daniel A Kim,et al.  Volume Overload in Heart Failure: An Evidence-Based Review of Strategies for Treatment and Prevention. , 2015, Mayo Clinic proceedings.

[66]  P. Ponikowski,et al.  Recommendations on pre‐hospital & early hospital management of acute heart failure: a consensus paper from the Heart Failure Association of the European Society of Cardiology, the European Society of Emergency Medicine and the Society of Academic Emergency Medicine , 2015, European journal of heart failure.

[67]  B. Davis,et al.  The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials , 2015, European heart journal.

[68]  R. McKelvie,et al.  Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction , 2015, European journal of heart failure.

[69]  Akshay S. Desai,et al.  Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial , 2015, Circulation.

[70]  P. Ponikowski,et al.  Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency† , 2014, European heart journal.

[71]  J. McMurray,et al.  Comorbidities and differential diagnosis in heart failure with preserved ejection fraction. , 2014, Heart failure clinics.

[72]  L. Tavazzi,et al.  In-hospital and 1-year outcomes of acute heart failure patients according to presentation (de novo vs. worsening) and ejection fraction. Results from IN-HF Outcome Registry. , 2014, International journal of cardiology.

[73]  M. Komajda,et al.  Controversies in cardiovascular medicine Heart failure with preserved ejection fraction : a clinical dilemma , 2014 .

[74]  Sanjiv J Shah,et al.  Spironolactone for heart failure with preserved ejection fraction. , 2014, The New England journal of medicine.

[75]  S. Solomon,et al.  Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM‐Preserved , 2014, European journal of heart failure.

[76]  J. McMurray,et al.  Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure). , 2013, Journal of the American College of Cardiology.

[77]  M. Drazner,et al.  2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. , 2013, Circulation.

[78]  F. Alla,et al.  Effectiveness of a multidimensional home nurse led heart failure disease management program--a French nationwide time-series comparison. , 2013, International journal of cardiology.

[79]  Piotr Ponikowski,et al.  EURObservational Research Programme: regional differences and 1‐year follow‐up results of the Heart Failure Pilot Survey (ESC‐HF Pilot) , 2013, European journal of heart failure.

[80]  I. Piña,et al.  Forecasting the Impact of Heart Failure in the United States: A Policy Statement From the American Heart Association , 2013, Circulation. Heart failure.

[81]  Manesh R. Patel,et al.  Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. , 2013, JAMA.

[82]  V. Roger,et al.  Contemporary trends in heart failure with reduced and preserved ejection fraction after myocardial infarction: a community study. , 2013, American journal of epidemiology.

[83]  E. Braunwald,et al.  Heart failure. , 2013, JACC. Heart failure.

[84]  S. Solomon,et al.  The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial , 2012, The Lancet.

[85]  K. Sliwa,et al.  The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries. , 2012, Archives of internal medicine.

[86]  J. Ménard,et al.  Eplerenone survival benefits in heart failure patients post-myocardial infarction are independent from its diuretic and potassium-sparing effects. Insights from an EPHESUS (Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study) substudy. , 2011, Journal of the American College of Cardiology.

[87]  Stefan D Anker,et al.  Telemedicine and remote management of patients with heart failure , 2011, The Lancet.

[88]  L. Stevenson,et al.  Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial , 2011, The Lancet.

[89]  Bertram Pitt,et al.  Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial , 2011, European heart journal.

[90]  C. Yancy,et al.  Relationship between early physician follow-up and 30-day readmission among Medicare beneficiaries hospitalized for heart failure. , 2010, JAMA.

[91]  P. Ponikowski,et al.  Ferric carboxymaltose in patients with heart failure and iron deficiency. , 2009, The New England journal of medicine.

[92]  J Michael Gaziano,et al.  Relation between modifiable lifestyle factors and lifetime risk of heart failure. , 2009, JAMA.

[93]  Susan Anderson,et al.  Irbesartan in patients with heart failure and preserved ejection fraction. , 2008, The New England journal of medicine.

[94]  Karl Swedberg,et al.  Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure , 2007, Circulation.

[95]  N. Freemantle,et al.  FASTTRACK : The perindopril in elderly people with chronic heart failure (PEP-CHF) study , 2006 .

[96]  S. Yusuf,et al.  Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials , 2006, The Lancet.

[97]  Peter C Austin,et al.  Outcome of heart failure with preserved ejection fraction in a population-based study. , 2006, The New England journal of medicine.

[98]  V. Roger,et al.  Trends in prevalence and outcome of heart failure with preserved ejection fraction. , 2006, The New England journal of medicine.

[99]  Karl Swedberg,et al.  Influence of Ejection Fraction on Cardiovascular Outcomes in a Broad Spectrum of Heart Failure Patients , 2005, Circulation.

[100]  M David Tilson,et al.  The polymorphonuclear leukocyte and the abdominal aortic aneurysm: a neglected cell type and a neglected disease. , 2005, Circulation.

[101]  J. McMurray,et al.  Multidisciplinary strategies for the management of heart failure patients at high risk for admission: a systematic review of randomized trials. , 2004, Journal of the American College of Cardiology.

[102]  F. Turnbull.  Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials , 2003, The Lancet.

[103]  Karl Swedberg,et al.  Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial , 2003, The Lancet.

[104]  S. Silver,et al.  Heart Failure , 1937, The New England journal of medicine.